TGF‐β1 has been identified as a key profibrotic factor in airway fibrosis, and its inhibition has been explored as a therapeutic approach for various fibrotic diseases, including idiopathic pulmonary fibrosis and renal fibrosis [23, 24]. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.